

Press Release

16 January 2024 14:00:00 CET

Sahlgrenska Hospital invests in precision diagnostics with QluCore Insights

QluCore, a driving force in software development for precision diagnostics of cancer, has signed an agreement with Sahlgrenska Hospital in Gothenburg, Sweden. The hospital will use the QluCore Insights software to improve the diagnosis of acute lymphoblastic leukemia (ALL) in children. ALL is the most common form of childhood leukemia, affecting 90% of children diagnosed with leukemia.

With existing customers in Denmark and Italy, this agreement marks an expansion for QluCore as it secures its first precision diagnostics order in Sweden. The QluCore goal is to help customers develop analyses that contribute to a more accurate diagnosis, enabling clinicians to make more informed treatment choices.

"Our solutions will facilitate and enable improved diagnostics of cancer; in this case, acute lymphoblastic leukemia (ALL). The goal is to make it easier for the doctor to make a diagnosis and decide how the disease should be treated, and for the patients to receive more precise treatment," says Carl-Johan Ivarsson, CEO of QluCore.

Cancer diagnostics are changing rapidly and QluCore is at the forefront of this development. The QluCore software, unique in its field, combines advanced visualization, mathematics and biology to make it more quickly and easily accessible to the user.

QluCore solutions are also available for research and progress towards CE marking is ongoing. The company's advanced software creates the conditions for faster, better and more accurate cancer diagnostics where the use of AI-based machine learning makes it possible to better categorize patients into more detailed subgroups.

Certified Advisor

FNCA Sweden AB

Web: www.fnca.se

Contacts

Press contact:

Carys Geer/ Mandy Brooks

Brookscomm

Phone: +44 (0) 1483 537 890

Email: carys@brookscomm.com

QluCore contact:

Carl-Johan Ivarsson, CEO

Phone: +46 (0) 46 286 31 14

Email: carl-johan.ivarsson@qlucore.com

About QluCore

QluCore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. QluCore's mission is to make it easier to analyze the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. QluCore Omics Explorer software is a easy to use bioinformatics software for research in the life science, plant- and biotech industries, as well as in academia. QluCore Diagnostics and QluCore Insights are software platforms with built in AI-based machine learning for multi-omics companion and precision diagnostics. QluCore was founded in 2007 in Lund, Sweden and has customers in about 25 countries around the world, with sales offices in Europe and North America, and distribution in several countries in Asia. QluCore is listed on the Nasdaq First North Growth market. www.qlucore.com

Image Attachments

[PR 2023 01 Leukemia](#)

Attachments

[Sahlgrenska Hospital invests in precision diagnostics with QluCore Insights](#)